Tags: Cancer | lung | cancer | NSCLC | immunotherapy | nivolumab | survival

Lung Cancer Drug Shows Effectiveness in Trial

Thursday, 30 October 2014 12:21 PM


Treatment of advanced squamous cell non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb Co's experimental immunotherapy nivolumab led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data being presented at a medical meeting.
While the study called CheckMate-063 did not compare nivolumab with another drug or placebo, the historical one-year survival rate for patients like those in the trial, whose cancer had progressed after treatment with two or more prior therapies, is between 5.5 percent and 18 percent, the company said.
Nivolumab belongs to a highly promising new class of drugs called PD-1 inhibitors that block a tumor's ability to camouflage itself, allowing the body's immune system to recognize and attack the cancer. Merck & Co last month received the first U.S. approval of a drug from the class to treat advanced melanoma - the deadliest form of skin cancer.
"The Phase II findings from CheckMate-063 are encouraging as there are no effective treatment options for patients with refractory squamous cell lung cancer after their disease has progressed through two prior therapies," Dr Suresh Ramalingam, director of Medical Oncology at Winship Cancer Institute of Emory University, said in a statement.
Bristol-Myers, which has proposed the brand name Opdivo for nivolumab, plans to use the data as part of its rolling submissions seeking U.S. and European approvals.
The median overall survival in the 117-patient trial was 8.2
months. The median duration of response had not yet been reached.
The objective response rate (ORR), which was the primary goal of the trial, was 15 percent as assessed by an independent review committee. That compares with historical expectations in the single digits, the company said. ORR was defined as reduction of the target lesion of at least 30 percent with no new lesions.
The results were scheduled to be reported on Friday at a thoracic oncology meeting in Chicago.
Fatigue, lung tissue inflammation and diarrhea were among the most common adverse side effects reported. The discontinuations rate due to drug-related side effects was 12 percent, and there were two drug-related deaths, the company reported.
Lung cancer is the leading cause of cancer deaths globally, with about 1.5 million each year, according to the World Health Organization. NSCLC accounts for about 85 percent of lung cancer cases.
 

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Treatment of advanced squamous cell non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb Co's experimental immunotherapy nivolumab led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data being presented at a medical...
lung, cancer, NSCLC, immunotherapy, nivolumab, survival
380
2014-21-30
Thursday, 30 October 2014 12:21 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved